Search results for: Competition
Filter search results
OHE Annual Lecture 2019: The Evolution of U.S. Policy Responses to the Opioid Epidemic
1 August 2019
…abuse care, long term care financing policy, health care competition and implementation of health reform, and disability policy. He served as the deputy assistant secretary for planning and evaluation at…
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
…care systems anywhere in the industrialized world.” A key question, then, is whether these other countries achieve lower prices via market-based competition. We describe and compare key aspects of the…
OHE has an Opening for an Industrial Economist
20 November 2019
…and competition in the health care and the pharmaceutical markets Health econometrics and real-world evidence Applications must be received by close of business on Wednesday 4th December 2019. Interviews for shortlisted candidates will…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…health economist. He has also acted as an advisor to a number of governments and governmental bodies (including the UK government, The UK Competition Commission (investigating private health care delivery in…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…industry profits) to optimal CETs. The model interprets cost-reducing policy tools and competition among medicines still on patent as an increase in bargaining power of the payer. Consequently, the set…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
…via IBP would put pressure on payer budgets, although a subset believed that in the long run IBP will generate competition and lead to lower prices. There was a wide…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…buyers, also empowered to design market policy and regulation, payers/purchasers have a significant degree of bargaining power. Governments can apply budget caps and other forms of cos t-containment measures, and competition among medicines…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…direct cost savings, and degree of in-class and post-patent expiry competition for orphan and non-orphan drugs). In addition, society still needs to tackle the broader issue of determining appropriate priorities…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
…for drugs that are fairly priced, in order to leverage competition in hopes of even lower prices for all drugs in the class. Prior authorisation remains a reasonable policy tool,…